ResearcherFirst People's Hospital of JingzhouActive in the last 2 years
Peng Wan
Matched on OpenAlex author ID A5121287476.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 2
2024: 1 paper · 2025: 2 papers
Papers 3
- Very early recurrence after pancreatic cancer resection: Unmasking the "biological R2" enigma and rethinking prognostic paradigms. First author DOI 10.4240/wjgs.v17.i12.114403↗
- Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.5306/wjco.v16.i2.98079↗
- Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. Co-author DOI 10.5306/wjco.v15.i7.859↗
Closest collaborators
The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Shi-Qiong Zhou · 3 shared papers, 2024–2025
- Paper Very early recurrence after pancreatic cancer resection: Unmasking the "biological R2" enigma and rethinking prognostic… DOI 10.4240/wjgs.v17.i12.114403↗
- Paper Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarci… DOI 10.5306/wjco.v16.i2.98079↗
- Paper Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocar… DOI 10.5306/wjco.v15.i7.859↗
- Qinghua Ke · 3 shared papers, 2024–2025
- Paper Very early recurrence after pancreatic cancer resection: Unmasking the "biological R2" enigma and rethinking prognostic… DOI 10.4240/wjgs.v17.i12.114403↗
- Paper Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarci… DOI 10.5306/wjco.v16.i2.98079↗
- Paper Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocar… DOI 10.5306/wjco.v15.i7.859↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.